Ionizing Radiation Exposure among Kidney Transplant Recipients Due to Medical Imaging during the Pretransplant Evaluation

Kim N. Nguyen,* Anup M. Patel,* and Francis L. Weng†

Summary

**Background and objectives** Kidney transplant recipients are at increased risk for malignancies. One recognized risk for malignancy is ionizing radiation. The purpose of this study was to determine, among kidney transplant recipients, the medical imaging procedures that contribute to radiation exposure and their cumulative radiation exposure, as a result of their pretransplant evaluation.

**Design, setting, participants, & measurements** Medical records of patients who received a first, kidney-alone transplant during 2008 at a single transplant center were examined. This study identified medical imaging procedures that were performed as prerequisites for deceased donor wait-listing or receipt of live donor kidney transplants and to maintain active status on the wait list. Frequencies of medical imaging procedures and cumulative effective doses of radiation were calculated.

**Results** Among the 172 kidney transplant recipients, 905 procedures were performed. Seventy patients (40.7%) were exposed to low dose (0–20 mSv), 51 (29.7%) were exposed to moderate dose (>20–50 mSv), 28 (16.3%) were exposed to high dose (>50–100 mSv), and 23 (13.4%) were exposed to very high dose (>100 mSv) cumulative effective radiation. Nuclear stress tests accounted for 82.9% of the total radiation exposure. In multivariate analysis, older age, diabetes, and black race were associated with exposure to >20 mSv radiation during the pretransplant evaluation.

**Conclusions** Kidney transplant recipients are exposed to large amounts of ionizing radiation from medical imaging during the pretransplant evaluation. The effects of radiation upon malignancy risk and strategies to reduce this radiation exposure warrant further investigation.

Introduction

Among recipients of kidney transplants, cancer is the third leading cause of death with a functioning graft (1). The increased risk of cancer among transplant recipients is multi-factorial in etiology (2). There is a well recognized link to the cumulative dose of immunosuppression and the increased risk for skin cancers, lymphoproliferative disease, and solid organ tumors among transplant recipients.

Ionizing radiation is a well established risk for cancer (3). The United Nations Scientific Committee on the Effects of Atomic Radiation estimated that the individual annual effective radiation dose from natural sources is slightly <3 mSv (4). In the United States, medical radiation exposure is increasingly the largest source of exposure from human-made sources of radiation. Mettler et al. showed essentially equal contributions from medical radiation exposure and natural background radiation exposure in the United States (5). Occupational radiation exposure is monitored and restricted to effective doses of 100 mSv every 5 years (20 mSv/yr), with a maximum of 50 mSv allowed in any given year (6).

Kidney transplant recipients, who already have an increased risk of cancer, may receive high doses of radiation from radiologic procedures. Previous studies have reported increased radiation exposure from medical imaging among the general population (7,8). In more recent studies, increased radiation exposure has been identified in hemodialysis patients and post-transplant recipients (9–11).

Kidney transplant recipients may also receive especially high doses of medical radiation due to their extensive pretransplant testing. In this study, we sought to estimate the cumulative radiation exposure as a result of the pretransplant work-up. In addition, we determined the types and numbers of medical imaging procedures that contribute to radiation exposure, to help identify strategies that may help minimize exposure.

Materials and Methods

**Study Design**

We conducted a retrospective cohort study of all adults (aged >18 years) who received a kidney-alone...
transplant from January 1, 2008 through December 31, 2008 at Saint Barnabas Medical Center in Livingston, New Jersey. We excluded recipients of prior kidney transplants, recipients of other solid organ transplants, and recipients of simultaneous pancreas-kidney transplants. The human subjects Institutional Review Board at Saint Barnabas Medical Center approved the study protocol.

**Determination of Radiation Exposure**

To identify pretransplant exposure to medical radiation, we examined medical records to identify the types and number of medical imaging procedures performed before transplantation. We identified all procedures that expose patients to medical radiation (plain radiography, computed tomography, nuclear medicine imaging, and fluoroscopic procedures) and were performed as prerequisites for placement on our deceased donor waiting list or receipt of a live donor kidney transplant or to maintain active status on the waiting list. We excluded procedures that were not required for placement on our waiting list (e.g., hemodialysis arteriovenous fistulogram) and those specifically delivered

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Low Dose (0–20 mSv)</th>
<th>Moderate Dose (&gt;20–50 mSv)</th>
<th>High Dose (&gt;50–100 mSv)</th>
<th>Very High Dose (&gt;100 mSv)</th>
<th>P Value</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total participants</td>
<td>70 (40.7)</td>
<td>51 (29.7)</td>
<td>28 (16.3)</td>
<td>23 (13.4)</td>
<td>0.68</td>
<td>172</td>
</tr>
<tr>
<td>Female</td>
<td>31 (44.3)</td>
<td>22 (43.1)</td>
<td>11 (39.3)</td>
<td>7 (30.4)</td>
<td>0.07</td>
<td>71 (41.3)</td>
</tr>
<tr>
<td>Black</td>
<td>16 (22.9)</td>
<td>22 (43.1)</td>
<td>10 (35.7)</td>
<td>12 (52.7)</td>
<td>0.07</td>
<td>60 (34.9)</td>
</tr>
<tr>
<td>Age at evaluation (yr)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18–40</td>
<td>27 (38.6)</td>
<td>4 (7.8)</td>
<td>1 (3.6)</td>
<td>3 (13.0)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>&gt;40–50</td>
<td>20 (28.6)</td>
<td>14 (27.5)</td>
<td>4 (14.3)</td>
<td>3 (13.0)</td>
<td>0.35</td>
<td>20 (28.6)</td>
</tr>
<tr>
<td>&gt;50–60</td>
<td>15 (21.4)</td>
<td>22 (43.1)</td>
<td>20 (71.4)</td>
<td>9 (39.1)</td>
<td>0.36</td>
<td>41 (23.8)</td>
</tr>
<tr>
<td>&gt;60</td>
<td>8 (11.4)</td>
<td>11 (21.6)</td>
<td>3 (10.7)</td>
<td>8 (34.8)</td>
<td>0.01</td>
<td>19 (10.5)</td>
</tr>
<tr>
<td>Etiology of renal disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>8 (11.4)</td>
<td>20 (39.2)</td>
<td>8 (28.6)</td>
<td>13 (56.5)</td>
<td>0.26</td>
<td>49 (28.5)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>16 (22.9)</td>
<td>14 (27.5)</td>
<td>6 (21.4)</td>
<td>7 (30.4)</td>
<td>0.43</td>
<td>25 (14.9)</td>
</tr>
<tr>
<td>GN</td>
<td>29 (41.4)</td>
<td>8 (15.7)</td>
<td>7 (25.0)</td>
<td>2 (9.7)</td>
<td>0.46</td>
<td>26 (16.7)</td>
</tr>
<tr>
<td>Other</td>
<td>17 (24.3)</td>
<td>9 (17.7)</td>
<td>7 (25.0)</td>
<td>1 (4.4)</td>
<td>0.34</td>
<td>19 (10.5)</td>
</tr>
<tr>
<td>Dialysis status at time of evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.26</td>
<td></td>
</tr>
<tr>
<td>Pre-emptive</td>
<td>40 (57.1)</td>
<td>20 (39.2)</td>
<td>10 (35.7)</td>
<td>12 (52.2)</td>
<td>0.82</td>
<td>47 (77.7)</td>
</tr>
<tr>
<td>On hemodialysis</td>
<td>26 (37.1)</td>
<td>29 (56.9)</td>
<td>16 (57.1)</td>
<td>11 (47.8)</td>
<td>0.82</td>
<td>47 (77.7)</td>
</tr>
<tr>
<td>On peritoneal dialysis</td>
<td>4 (5.7)</td>
<td>2 (3.9)</td>
<td>2 (7.1)</td>
<td>0 (0)</td>
<td>0.08</td>
<td>4 (7.1)</td>
</tr>
<tr>
<td>Transplant type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Deceased donor</td>
<td>27 (34.3)</td>
<td>30 (58.8)</td>
<td>18 (64.3)</td>
<td>18 (78.3)</td>
<td>0.90</td>
<td>52 (33.7)</td>
</tr>
<tr>
<td>Living donor</td>
<td>46 (65.7)</td>
<td>21 (41.2)</td>
<td>10 (35.7)</td>
<td>5 (21.7)</td>
<td>0.82</td>
<td>47 (77.7)</td>
</tr>
<tr>
<td>Charlson comorbidity index</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.07</td>
<td></td>
</tr>
<tr>
<td>2–3</td>
<td>49 (70.0)</td>
<td>23 (45.1)</td>
<td>16 (57.1)</td>
<td>6 (26.1)</td>
<td>0.94</td>
<td>54 (70.7)</td>
</tr>
<tr>
<td>4–5</td>
<td>17 (24.3)</td>
<td>17 (33.3)</td>
<td>6 (21.4)</td>
<td>11 (47.8)</td>
<td>0.51</td>
<td>29 (37.1)</td>
</tr>
<tr>
<td>6–8</td>
<td>4 (5.7)</td>
<td>11 (21.6)</td>
<td>6 (21.4)</td>
<td>6 (26.1)</td>
<td>0.27</td>
<td>15 (7.7)</td>
</tr>
<tr>
<td>ABO blood type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.08</td>
<td></td>
</tr>
<tr>
<td>Group A</td>
<td>31 (44.3)</td>
<td>24 (47.1)</td>
<td>11 (39.3)</td>
<td>3 (13.0)</td>
<td>0.69</td>
<td>40 (16.1)</td>
</tr>
<tr>
<td>Group AB</td>
<td>5 (7.1)</td>
<td>0 (0)</td>
<td>2 (7.1)</td>
<td>0 (0)</td>
<td>7 (4.1)</td>
<td></td>
</tr>
<tr>
<td>Group B</td>
<td>8 (11.4)</td>
<td>7 (13.7)</td>
<td>4 (14.3)</td>
<td>7 (30.4)</td>
<td>0.26</td>
<td>15 (7.7)</td>
</tr>
<tr>
<td>Group O</td>
<td>26 (37.1)</td>
<td>20 (39.2)</td>
<td>11 (39.3)</td>
<td>13 (56.5)</td>
<td>0.70</td>
<td>40 (16.1)</td>
</tr>
<tr>
<td>Peak panel reactive antibody (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>28 (40.0)</td>
<td>25 (49.0)</td>
<td>12 (42.9)</td>
<td>15 (65.2)</td>
<td>0.80</td>
<td>46 (16.5)</td>
</tr>
<tr>
<td>1–19</td>
<td>22 (31.4)</td>
<td>13 (25.5)</td>
<td>8 (28.6)</td>
<td>2 (8.7)</td>
<td>0.45</td>
<td>26 (16.2)</td>
</tr>
<tr>
<td>20–79</td>
<td>15 (21.4)</td>
<td>11 (21.6)</td>
<td>3 (10.7)</td>
<td>3 (13.0)</td>
<td>0.32</td>
<td>18 (6.8)</td>
</tr>
<tr>
<td>80–100</td>
<td>26 (37.1)</td>
<td>20 (39.2)</td>
<td>11 (39.3)</td>
<td>3 (13.0)</td>
<td>0.15</td>
<td>15 (6.8)</td>
</tr>
<tr>
<td>Time from initial evaluation to time</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>of transplant (mo)</td>
<td>0–12</td>
<td>41 (58.6)</td>
<td>20 (39.2)</td>
<td>1 (3.6)</td>
<td>0 (0)</td>
<td>62 (36.1)</td>
</tr>
<tr>
<td>&gt;12–24</td>
<td>11 (15.7)</td>
<td>9 (17.7)</td>
<td>7 (25.0)</td>
<td>0 (0)</td>
<td>0.27</td>
<td>15 (7.7)</td>
</tr>
<tr>
<td>&gt;24–48</td>
<td>11 (15.7)</td>
<td>10 (19.6)</td>
<td>7 (25.0)</td>
<td>5 (21.7)</td>
<td>0.33</td>
<td>19 (12.1)</td>
</tr>
<tr>
<td>&gt;48</td>
<td>7 (10.0)</td>
<td>12 (23.5)</td>
<td>13 (46.4)</td>
<td>18 (78.3)</td>
<td>0.50</td>
<td>29 (18.1)</td>
</tr>
</tbody>
</table>

Data are given as n (%).
for therapeutic purposes (e.g., high dose radiation for breast cancer or prostate cancer).

Certain procedures have a wide range of effective radiation dose dependent upon several factors. Calculation of effective dose of radiation is well described (6,12–16). For nuclear stress tests (NSTs), we calculated the effective dose of radiation using the addenda to International Commission on Radiologic Protection publication 53, to give a more accurate assessment of radiation exposure (17). In cases in which data were missing, we imputed the lowest known amount of radionuclide given to calculate the effective radiation dose. To estimate the radiation exposure for x-rays and noncardiac nuclear medicine scans, we used the lowest estimates of effective dose of radiation measured in millisieverts from published literature. For the computed tomography procedures, the dose length product data were not available, so we used estimates of effective dose of radiation from published literature.

We categorized the cumulative effective radiation doses for the study population into the following groups: low dose (0–20 mSv), moderate dose (>20–50 mSv), high dose (>50–100 mSv), and very high dose (>100 mSv). In univariable logistic regression, our outcome was moderate or higher doses (>20 mSv) of radiation exposure during the pretransplant period.

Analyses were performed using Stata 9.0 statistical software (Stata Corp, College Station, TX). Two-sided $P$ values <0.05 were considered statistically significant. Categorical variables were expressed as proportions, and their values across groups (e.g., total cumulative radiation dose) were compared using chi-squared testing. Continuous variables that were not normally distributed were expressed as medians with 25%–75% interquartile ranges (IQRs) and analyzed as categorical (ordinal) variables. We used logistic regression to model associations between our outcome (exposure to large amounts of cumulative radiation) and possible predictors. Candidate variables with $P$<0.20 in the unadjusted analyses were eligible for the multivariable model. We generated the multivariable model using a stepwise, backward elimination method. We assessed the significance of each variable in the nested models using the likelihood ratio test and the Wald statistic. Variables with adjusted $P$<0.10 were retained in the final model.

**Results**

**Study Population**

During the study period, 208 kidney transplants were performed at our center, and 172 of the kidney transplant recipients met our inclusion criteria. The demographic and medical characteristics of the 172 patients are shown in Table 1. The median age was 51.2 years (IQR, 43.3–58.0) at evaluation and 54.0 years (IQR, 44.7–60.9) at transplantation. The median number of years of follow-up was 3.7 years (IQR, 2.1–5.2).

**Types and Number of Radiologic Tests and Procedures**

A total of 905 procedures were performed in 172 patients during the study (Figure 1). Plain radiography (56.8%) and

![Figure 1. Types and number of radiologic procedures.](image-url)
nuclear medicine procedures (28.4%) accounted for the majority of the procedures. The median number of procedures per patient was 5.

Radiation Exposure
The total radiation exposure before transplant for the study group was approximately 7900.45 mSv. The median cumulative radiation exposure for each patient was 28.8 mSv (IQR, 12.0–60.8) during the 4 years of follow-up. The majority of the total radiation exposure was made up of nuclear medicine testing. The main contributor of radiation exposure from nuclear medicine tests was NST (Figure 2). Although the majority of procedures were from plain radiography, these procedures contributed the least amount of total radiation exposure.

Overall, 70 patients (40.7%) were exposed to low dose (0–20 mSv) cumulative effective radiation, 51 (29.7%) were exposed to moderate dose (>20–50 mSv) radiation, 28 (16.3%) were exposed to high dose (>50–100 mSv) radiation, and 23 (13.4%) were exposed to very high dose radiation (>100 mSv).

We calculated the annual cumulative effective dose of radiation exposure among the 110 transplant recipients with at least 1 year of pretransplant follow-up. We did not calculate annual radiation exposure among the other 62 patients, given that they had <1 year of follow-up between their initial transplant evaluation and receipt of a kidney transplant. Among these 110 transplant recipients, the median annual radiation exposure was 12.6 mSv/yr (IQR, 6.0–27.9 mSv/yr). Of the 110 patients, 15 (13.6%) had 0–3 mSv/yr, 57 (51.8%) had >3–20 mSv/yr, 31 (28.2%) had >20–50 mSv/yr, and 7 (6.4%) had >50–100 mSv/yr of radiation exposure.

Univariable and Multivariable Regression of Baseline Factors Associated with Increased Radiation Exposure
The likelihood of increased dose radiation exposure varied according to demographic and medical factors (Figure 3 and Table 1). We excluded type of transplant and time until transplant from the regression models, however, because these variables are unknown at baseline at the time of the initial transplant evaluation.

In univariable logistic regression, moderate or higher doses (>20 mSv) of radiation exposure was more common among patients with the following characteristics: black race, older age, diabetes as the cause of their kidney disease, on maintenance hemodialysis at the time of initial transplant evaluation, and higher Charlson comorbidity index scores. In the multivariable logistic regression model, black race, older age, diabetes as the cause of ESRD were independently associated with moderate or higher doses (>20 mSv) of radiation exposure (Table 2).
Discussion

Our study showed that more than half of kidney transplant recipients were exposed to moderate or higher dose (>20 mSv) ionizing radiation during their pretransplant work-up. Compared with the general population, our transplant recipients received 5 times greater cumulative effective radiation exposure per year (7).

The purpose of our study was to assess the radiation exposure before kidney transplant due to transplant evaluation. The study excludes radiation exposure from tests ordered by general nephrologists as part of routine CKD/ESRD care (e.g., fistulogram). Transplant centers have little, if any, control over the procedures ordered as part of routine nephrology care. The radiation exposure of the study patients would potentially be even higher if we included procedures ordered by the general nephrologists (or other health care providers). However, our objective was to determine radiation exposure stemming from tests ordered by the transplant physician, because this is modifiable by an individual transplant center.

NST accounted for the majority of radiation exposure in our study population. The pretransplant protocol at our institution is guided by the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients (18). Our protocol suggests noninvasive cardiac screening annually for diabetic candidates and biennially for candidates aged >50 years with cardiac risk factors. Not surprisingly, ESRD due to diabetes mellitus, older age at time of evaluation, and total years from evaluation to time of transplant resulted in increased risk for exposure to moderate or higher dose (>20 mSv) of ionizing radiation.

Transplant candidates undergo intense cardiovascular evaluation due to the high prevalence of cardiovascular disease (19,20). The optimal frequency of cardiac screening for potential transplant candidates is controversial. Compared with the KDOQI guidelines, the American College of Cardiology/American Heart Association guidelines

| Table 2. Multivariable analysis of baseline factors associated with >20 mSv total radiation exposure |
| Variable | Odds Ratio (95% Confidence Interval) | P Value |
| Black | 3.39 (1.51–7.59) | 0.003 |
| Age at time of transplant evaluation (vs ≤40) (yr) | 6.97 (2.65–18.3) | <0.001 |
| Diabetes as etiology of renal disease (vs cause other than diabetes) | 3.35 (1.39–8.09) | 0.01 |
recommend a less aggressive approach to cardiac screening (21). Friedman et al. demonstrated that this approach can reduce stress testing by 80% but may fail to identify individuals with single vessel coronary artery disease (22). However, the benefit of revascularization for single vessel coronary artery disease is unclear (23). The optimal modality of cardiac screening is also unclear. Indeed, a survey of transplant centers demonstrated a wide variety of preferred cardiac screening, with 7% using exercise stress without imaging, 15% using angiography, and the remainder using stress imaging (24). Stress echocardiography compares favorably to NST as a screening tool for cardiovascular disease and may help reduce radiation exposure in our patient population (25,26). The most favorable cardiac screening test remains controversial, and the preferred test is at the discretion of the individual transplant center (22,24,27).

This study has important limitations. First, this is a single-center retrospective analysis of a small study population. Transplant centers vary in their practices, especially in the use of NST, which was the major contributor to radiation exposure in our study. Our cardiac screening protocol is guided by the KDOQI guidelines and may be similar to other transplant centers’ protocols, but the choice of cardiac screening modality may differ.

Second, this was not a prospective analysis with long-term follow-up; therefore, we cannot determine whether increased cancers resulted from the radiation exposure the study population received. In addition, the majority of the data linking malignancy risk to radiation exposure is a result of a single high dose exposure (28,29). It is unclear if repeated exposure to low dose radiation from medical imaging over many years carries the same risk of malignancy as a single high dose exposure.

Third, we relied on published literature to estimate effective radiation dose for most radiologic procedures. This does not give a precise measurement for the individual or for the specific procedure. However, an individualized dose assessment was calculated for NST, which accounted for the vast majority of radiation exposure in the study. The use of the lowest published estimate of effective radiation dose in our study should minimize the possibility of overestimating the true radiation exposure.

Fourth, the use of mSv transparently reflects future malignancy risk due, in part, to the different radiosensitivities of different organs and tissues. However, given the wide variety of radiologic tests and the inability to calculate subject-specific exposure dose for all tests, we believe that effective dose was the best estimate of potential malignancy risk.

In conclusion, renal transplant patients are exposed to a significant amount of ionizing radiation as part of the pretransplant work-up. The cumulative ionizing radiation exposure over time can lead to potential health consequences in the future. The recognition of increased ionizing radiation exposure from medical imaging procedures should prompt clinicians to consider the use of alternative procedures with little or no radiation exposure that provide the same diagnostic capability. These strategies implemented in the pretransplant work-up may reduce the cumulative ionizing radiation exposure and decrease the incidence of potential future cancers among kidney transplant recipients.

Acknowledgments
A portion of this work was presented at the Annual Meeting of the American Society of Nephrology, held November 8–13, 2011, in Philadelphia, Pennsylvania.

Disclosures
None.

References


Received: April 23, 2012 Accepted: December 31, 2012

Published online ahead of print. Publication date available at www. cjasn.org.